title: High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer.
abstract: Studies by comparative genomic hybridization revealed that the chromosomal regions 3p25 and 8p11-p12 are recurrently amplified in bladder cancer. To investigate the prevalence of DNA copy number alterations in these chromosomal regions and study their clinical significance, we used probes for the RAF1 (3p25) and FGFR1 (8p12) genes for fluorescence in situ hybridization. A tissue microarray containing 2317 tumors was analyzed. The analysis revealed RAF1 amplification in 4.0% and FGFR1 amplification in 3.4% of interpretable tumors. In addition, deletions were found at the 3p25 locus in 2.2% and at the 8p11-12 locus in 9.9% of interpretable tumors. Both amplifications and deletions of RAF1 and FGFR1 were significantly associated with high tumor grade (P < 0.0001), advanced stage (P < 0.0001), and poor survival (P < 0.05) if tumors of all of the stages where analyzed together. RAF1 amplifications were associated with subsequent tumor progression in pT1 carcinomas (P < 0.05). The marked differences in the frequency of all of the analyzed changes between pTa grade 1/grade 2 and pT1-4 carcinomas support the concept of these tumor groups representing different tumor entities.
authors.affiliation: Institute for Pathology and Urologic Clinics, University of Basel, Schoenbeinstrasse 40, CH-4031 Basel, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Simon
authors.forename: J
authors.initials: J
authors.lastname: Richter
authors.forename: U
authors.initials: U
authors.lastname: Wagner
authors.forename: A
authors.initials: A
authors.lastname: Fijan
authors.forename: J
authors.initials: J
authors.lastname: Bruderer
authors.forename: U
authors.initials: U
authors.lastname: Schmid
authors.forename: D
authors.initials: D
authors.lastname: Ackermann
authors.forename: R
authors.initials: R
authors.lastname: Maurer
authors.forename: G
authors.initials: G
authors.lastname: Alund
authors.forename: H
authors.initials: H
authors.lastname: Knönagel
authors.forename: M
authors.initials: M
authors.lastname: Rist
authors.forename: K
authors.initials: K
authors.lastname: Wilber
authors.forename: M
authors.initials: M
authors.lastname: Anabitarte
authors.forename: F
authors.initials: F
authors.lastname: Hering
authors.forename: T
authors.initials: T
authors.lastname: Hardmeier
authors.forename: A
authors.initials: A
authors.lastname: Schönenberger
authors.forename: R
authors.initials: R
authors.lastname: Flury
authors.forename: P
authors.initials: P
authors.lastname: Jäger
authors.forename: J L
authors.initials: JL
authors.lastname: Fehr
authors.forename: P
authors.initials: P
authors.lastname: Schraml
authors.forename: H
authors.initials: H
authors.lastname: Moch
authors.forename: M J
authors.initials: MJ
authors.lastname: Mihatsch
authors.forename: T
authors.initials: T
authors.lastname: Gasser
authors.forename: G
authors.initials: G
authors.lastname: Sauter
mesh_terms: D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D005784:Gene Amplification; D017353:Gene Deletion; D018628:Gene Dosage; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D009367:Neoplasm Staging; D011379:Prognosis; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D051496:Receptor, Fibroblast Growth Factor, Type 1; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics*; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D017468:Receptors, Fibroblast Growth Factor; C496348:FGFR1 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D019908:Proto-Oncogene Proteins c-raf